EGFR in colorectal cancer
3 EU-approved indications in colorectal cancer need a EGFR result: cetuximab (metastatic), cetuximab (1st line, metastatic) and cetuximab (3rd line+, metastatic).
Line of therapy
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| EGFR3 | ||||
Erbitux | RAS wild-type, EGFR-expressing | + FOLFOX | 1L metastatic | None |
Erbitux | RAS wild-type, EGFR-expressing | Monotherapy | 3L+ metastatic | Failed oxaliplatin- and irinotecan-based therapy; Intolerant to irinotecan |
Erbitux | RAS wild-type, EGFR-expressing | + irinotecan-based chemotherapy | Any line metastatic | None |
5 approvals for CRC need no biomarker and apply whatever the result. All approvals for CRC
See also
Label wording3
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Cetuximab (Erbitux)
Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer • in combination with irinotecan-based chemotherapy,
- Cetuximab (Erbitux)
Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer • in combination with irinotecan-based chemotherapy, • in first-line in combination with FOLFOX,
- Cetuximab (Erbitux)
Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer • in combination with irinotecan-based chemotherapy, • in first-line in combination with FOLFOX, • as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.